Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
Pyxis Oncology (PYXS) Stock Price & Analysis
299 Followers
PYXS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.35 - $6.85
Previous Close$3.2
Volume893.22K
Average Volume (3M)577.61K
Market Cap
$188.44M
Enterprise Value$52.20M
Total Cash (Recent Filing)$157.03M
Total Debt (Recent Filing)$20.78M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Aug 12, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding58,888,473
10 Day Avg. Volume520,453
30 Day Avg. Volume577,609
Standard Deviation0.34
R-Squared0.04
Alpha-0.00434
Financial Highlights & Ratios
Price to Book (P/B)1.96
Price to Sales (P/S)12.29
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit29.00
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$8.75Price Target Upside197.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Pyxis Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEncouraging early clinical activity of PYX-201 supports the view that it will exhibit meaningful clinical benefit at higher dose levels.
Financial PerformanceThe company reported total revenues of $16M, compared to the consensus estimate of $3.3M.
Pipeline And DevelopmentPyxis is the only company with a Siglec-15 inhibitor in active clinical development.
Bears Say
Investor SentimentThe stock witnessed a decline following the update, reflecting investor disappointment in the delay.
Project DelaysInitial Ph 1 dose-escalation data for PYX-201 is now expected in fall of 2024, a delay from the first half of the year.
Regulatory ChallengesRisks to the Buy rating include clinical, technology, regulatory, and competition challenges among others.
---
Ownership Overview
28.54% Insiders
3.38% Mutual Funds
29.15% Other Institutional Investors
38.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $1.35 and its highest was $6.85 in the past 12 months.
What is Pyxis Oncology’s market cap?
Currently, no data Available
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Aug 12, 2024 which is in 40 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on May 14, 2024. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.239 by $0.179.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -$0.33.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 58,888,474 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.239. Following the earnings report the stock price went down -2.098%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Among the largest hedge funds holding Pyxis Oncology’s share is Perceptive Advisors LLC. It holds Pyxis Oncology’s shares valued at N/A.
---
Pyxis Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (197.62% Upside)
$8.75 (197.62% Upside)
Blogger Sentiment
Bullish
PYXS Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.00%
12-Months-Change
Fundamentals
Return on Equity
-34.37%
Trailing 12-Months
Asset Growth
20.47%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
---
PYXS Stock 12 Month Forecast
Average Price Target
$8.75
▲(197.62% Upside)
Technical Analysis
Best Analysts Covering PYXS
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+26.05%
reiterated a buy rating 2 months ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +26.05% per trade.
---